HCV protein-induced cytokine predicts treatment outcomes in chronic hepatitis C virus infection

被引:0
|
作者
Krueger, Carla [1 ,2 ]
Collister, Mark [1 ,2 ]
Minuk, Gerald Y. [1 ]
Janke, Alyssa [1 ]
Lerner, Jordyn [1 ]
Wong, Stephen G. M. [1 ]
Rempel, Julia D. [1 ,2 ]
机构
[1] Univ Manitoba, Dept Med, Sect Hepatol, Winnipeg, MB R3E 3P4, Canada
[2] Univ Manitoba, Dept Immunol, Winnipeg, MB R3E 3P4, Canada
关键词
adipokines; core; hepatitis C virus; NS3; sustained viral response; TNF-alpha; NECROSIS-FACTOR-ALPHA; INDUCED INSULIN-RESISTANCE; RHEUMATOID-ARTHRITIS; SERUM-LEVELS; PSORIATIC-ARTHRITIS; ETANERCEPT THERAPY; ADIPONECTIN LEVELS; EGYPTIAN PATIENTS; INTERFERON-ALPHA; LIVER STEATOSIS;
D O I
10.1111/liv.12418
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Immune-mediated processes are thought to influence the efficacy of treatment in chronic hepatitis C virus (HCV) infection. This study evaluated the association of baseline immune responses with the achievement of a sustained viral response (SVR) upon pegylated interferon and ribavirin treatment. Methods: Baseline serum and peripheral blood mononuclear cells (PBMC) cytokine activity was assessed. Metabolic and liver injury parameters were evaluated as underlying factors. Results: Baseline demographics and disease parameters did not differ between the SVR - (n = 14) and SVR+ (n = 25) cohorts except for body mass index (BMI) values and liver injury scores. Baseline circulating TNF-alpha levels were three-fold higher with subsequent treatment failure vs. success (P = 0.124). Baseline peripheral blood mononuclear cells (PBMC, n = 25) were cultured with HCV core and non-structural (NS)3 proteins. Core (P = 0.0003) and NS3 (P = 0.018) induced greater TNF-alpha production within the SVR-, compared with the SVR+, cohorts. Similar findings were noted for interleukin (IL)-1 beta and IL-10 synthesis. Furthermore, HCV core-induced TNF-alpha synthesis correlated with patient BMI values (r = 0.489, P = 0.015). Core (r = 0.432, P = 0.065) and NS3 (r = 0.530, P = 0.020)-induced TNF-alpha displayed a positive relationship with serum adiponectin concentrations. In addition, lipopolysaccharide stimulated cytokine synthesis associated with BMI and adiponectin levels. Although unable to predict treatment outcomes, NS3-induced IL-6 synthesis and serum leptin concentrations corresponded to liver injury scores. Conclusion: An enhanced PBMC susceptibility to core and NS3-induced TNF-alpha synthesis at baseline was associated with treatment failure. This phenomenon appeared to involve the interaction of virally generated TNF-alpha activity and metabolic disease. In contrast, IL-6 activity and leptin levels may indicate liver damage.
引用
收藏
页码:E62 / E70
页数:9
相关论文
共 50 条
  • [31] SOFOSBUVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION
    Temesgen, Z.
    Talwani, R.
    Rizza, S. A.
    DRUGS OF TODAY, 2014, 50 (06) : 421 - 434
  • [32] Treatment optimization in chronic hepatitis C virus infection
    Fernandez Rodriguez, Conrado M.
    Alonso Lopez, Sonia
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2010, 33 (02): : 119 - 125
  • [33] Treatment strategies for chronic hepatitis C virus infection
    Akinori Kasahara
    Journal of Gastroenterology, 2000, 35 : 411 - 423
  • [34] Treatment strategies for chronic hepatitis C virus infection
    Kasahara, A
    JOURNAL OF GASTROENTEROLOGY, 2000, 35 (06) : 411 - 423
  • [35] DACLATASVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION
    Temesgen, Z.
    Rizza, S. A.
    DRUGS OF TODAY, 2015, 51 (05) : 277 - 288
  • [36] Treatment of chronic hepatitis C virus infection in children
    Chang, MH
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2000, 14 (02) : 341 - 350
  • [37] Predictors of Treatment for Hepatitis C Virus (HCV) Infection in Drug Users
    Reed, Carrie
    Stuver, Sherri O.
    Tumilty, Sheila
    Nunes, David
    Murray, Jessica E.
    Graham, Camilla S.
    Koziel, Margaret James
    Craven, Donald E.
    Skolnik, Paul R.
    Horsburgh, C. Robert, Jr.
    SUBSTANCE ABUSE, 2008, 29 (01) : 5 - 15
  • [38] Evaluation of Patient Preferences for Treatment Outcomes in Hepatitis C Virus (HCV)
    Lane, Suzanne
    Kirbach, Stephanie
    Gooch, Kathy
    Grinspan, Jessica
    Kallwitz, Eric R.
    Szabo, Shelagh M.
    Beusterien, Kathy
    HEPATOLOGY, 2012, 56 : 1025A - 1025A
  • [39] SIGNIFICANCE OF SERUM IGM ANTI-HEPATITIS-C VIRUS (HCV) IN CHRONIC HCV INFECTION
    BRILLANTI, S
    MASCI, C
    RICCI, P
    MIGLIOLI, M
    BARBARA, L
    GUT, 1991, 32 (10) : A1250 - A1250
  • [40] SIGNIFICANCE OF SERUM HEPATITIS-C VIRUS (HCV) RNA LEVELS IN CHRONIC HCV INFECTION
    LAU, JYN
    DAVIS, GL
    KNIFFEN, J
    QIAN, KP
    URDEA, MS
    CHAN, CS
    NEUWALD, PD
    WILBER, JC
    GASTROENTEROLOGY, 1993, 104 (04) : A935 - A935